87 related articles for article (PubMed ID: 8676339)
1. 2,4-Diarylpyrrolidine-3-carboxylic acids--potent ETA selective endothelin receptor antagonists. 1. Discovery of A-127722.
Winn M; von Geldern TW; Opgenorth TJ; Jae HS; Tasker AS; Boyd SA; Kester JA; Mantei RA; Bal R; Sorensen BK; Wu-Wong JR; Chiou WJ; Dixon DB; Novosad EI; Hernandez L; Marsh KC
J Med Chem; 1996 Mar; 39(5):1039-48. PubMed ID: 8676339
[TBL] [Abstract][Full Text] [Related]
2. Pyrrolidine-3-carboxylic acids as endothelin antagonists. 2. Sulfonamide-based ETA/ETB mixed antagonists.
Jae HS; Winn M; Dixon DB; Marsh KC; Nguyen B; Opgenorth TJ; von Geldern TW
J Med Chem; 1997 Sep; 40(20):3217-27. PubMed ID: 9379441
[TBL] [Abstract][Full Text] [Related]
3. Potent and selective non-benzodioxole-containing endothelin-A receptor antagonists.
Tasker AS; Sorensen BK; Jae HS; Winn M; von Geldern TW; Dixon DB; Chiou WJ; Dayton BD; Calzadila S; Hernandez L; Marsh KC; WuWong JR; Opgenorth TJ
J Med Chem; 1997 Jan; 40(3):322-30. PubMed ID: 9022798
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and activity of a series of pyrrolidine-3-carboxylic acid-based, highly specific, orally active ET(B) antagonists containing a diphenylmethylamine acetamide side chain.
Liu G; Kozmina NS; Winn M; von Geldern TW; Chiou WJ; Dixon DB; Nguyen B; Marsh KC; Opgenorth TJ
J Med Chem; 1999 Sep; 42(18):3679-89. PubMed ID: 10479299
[TBL] [Abstract][Full Text] [Related]
5. Structure-activity relationships of a novel series of orally active nonpeptide ETA and ETA/B endothelin receptor-selective antagonists.
Doherty AM; Patt WC; Repine J; Edmunds JJ; Berryman KA; Reisdorph BR; Walker DM; Haleen SJ; Keiser JA; Flynn MA
J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S358-61. PubMed ID: 8587414
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological properties of J-104132 (L-753,037), a potent, orally active, mixed ETA/ETB endothelin receptor antagonist.
Nishikibe M; Ohta H; Okada M; Ishikawa K; Hayama T; Fukuroda T; Noguchi K; Saito M; Kanoh T; Ozaki S; Kamei T; Hara K; William D; Kivlighn S; Krause S; Gabel R; Zingaro G; Nolan N; O'Brien J; Clayton F; Lynch J; Pettibone D; Siegl P
J Pharmacol Exp Ther; 1999 Jun; 289(3):1262-70. PubMed ID: 10336515
[TBL] [Abstract][Full Text] [Related]
7. Pharmacology of L-754,142, a highly potent, orally active, nonpeptidyl endothelin antagonist.
Williams DL; Murphy KL; Nolan NA; O'Brien JA; Pettibone DJ; Kivlighn SD; Krause SM; Lis EV; Zingaro GJ; Gabel RA
J Pharmacol Exp Ther; 1995 Dec; 275(3):1518-26. PubMed ID: 8531124
[TBL] [Abstract][Full Text] [Related]
8. Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective antagonist.
Murugesan N; Gu Z; Spergel S; Young M; Chen P; Mathur A; Leith L; Hermsmeier M; Liu EC; Zhang R; Bird E; Waldron T; Marino A; Koplowitz B; Humphreys WG; Chong S; Morrison RA; Webb ML; Moreland S; Trippodo N; Barrish JC
J Med Chem; 2003 Jan; 46(1):125-37. PubMed ID: 12502366
[TBL] [Abstract][Full Text] [Related]
9. Selective endothelin A receptor antagonists. 3. Discovery and structure-activity relationships of a series of 4-phenoxybutanoic acid derivatives.
Astles PC; Brealey C; Brown TJ; Facchini V; Handscombe C; Harris NV; McCarthy C; McLay IM; Porter B; Roach AG; Sargent C; Smith C; Walsh RJ
J Med Chem; 1998 Jul; 41(15):2732-44. PubMed ID: 9667964
[TBL] [Abstract][Full Text] [Related]
10. Pyrrolidine-3-carboxylic acids as endothelin antagonists. 4. Side chain conformational restriction leads to ET(B) selectivity.
von Geldern TW; Tasker AS; Sorensen BK; Winn M; Szczepankiewicz BG; Dixon DB; Chiou WJ; Wang L; Wessale JL; Adler A; Marsh KC; Nguyen B; Opgenorth TJ
J Med Chem; 1999 Sep; 42(18):3668-78. PubMed ID: 10479298
[TBL] [Abstract][Full Text] [Related]
11. Pyrrolidine-3-carboxylic acids as endothelin antagonists. 3. Discovery of a potent, 2-nonaryl, highly selective ETA antagonist (A-216546).
Liu G; Henry KJ; Szczepankiewicz BG; Winn M; Kozmina NS; Boyd SA; Wasicak J; von Geldern TW; Wu-Wong JR; Chiou WJ; Dixon DB; Nguyen B; Marsh KC; Opgenorth TJ
J Med Chem; 1998 Aug; 41(17):3261-75. PubMed ID: 9703472
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist.
Opgenorth TJ; Adler AL; Calzadilla SV; Chiou WJ; Dayton BD; Dixon DB; Gehrke LJ; Hernandez L; Magnuson SR; Marsh KC; Novosad EI; Von Geldern TW; Wessale JL; Winn M; Wu-Wong JR
J Pharmacol Exp Ther; 1996 Feb; 276(2):473-81. PubMed ID: 8632312
[TBL] [Abstract][Full Text] [Related]
13. New non-peptide endothelin-A receptor antagonists: synthesis, biological properties, and structure-activity relationships of 5-(dimethylamino)-N-pyridyl-,-N-pyrimidinyl-,-N-pyridazinyl-, and -N-pyrazinyl-1-naphthalenesulfonamides.
Bradbury RH; Bath C; Butlin RJ; Dennis M; Heys C; Hunt SJ; James R; Mortlock AA; Sumner NF; Tang EK; Telford B; Whiting E; Wilson C
J Med Chem; 1997 Mar; 40(6):996-1004. PubMed ID: 9083490
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationships of a novel class of endothelin receptor selective antagonists; 6-carboxy-2-isopropylamino-5,7-diarylcyclopenteno[1,2-b]pyridines.
Takahashi H; Ohtake N; Sakamoto T; Iino T; Kawanishi N; Nakamura M; Yoshizumi T; Niiyama K; Ozaki S; Okada H; Kano A; Takahashi H; Ishii Y; Okada M; Saito M; Sawazaki Y; Hayama T; Nishikibe M
Bioorg Med Chem Lett; 2004 Mar; 14(6):1503-7. PubMed ID: 15006391
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological profile of ZD1611, a novel, orally active endothelin ETA receptor antagonist.
Wilson C; Hunt SJ; Tang E; Wright N; Kelly E; Palmer S; Heys C; Mellor S; James R; Bialecki R
J Pharmacol Exp Ther; 1999 Sep; 290(3):1085-91. PubMed ID: 10454481
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity relationships of N2-aryl-3-(isoxazolylsulfamoyl)-2-thiophenecarboxamides as selective endothelin receptor-A antagonists.
Wu C; Chan MF; Stavros F; Raju B; Okun I; Castillo RS
J Med Chem; 1997 May; 40(11):1682-9. PubMed ID: 9171877
[TBL] [Abstract][Full Text] [Related]
17. Endothelin mediates superoxide production and vasoconstriction through activation of NADPH oxidase and uncoupled nitric-oxide synthase in the rat aorta.
Loomis ED; Sullivan JC; Osmond DA; Pollock DM; Pollock JS
J Pharmacol Exp Ther; 2005 Dec; 315(3):1058-64. PubMed ID: 16144972
[TBL] [Abstract][Full Text] [Related]
18. Nonpeptide endothelin receptor antagonists. XI. Pharmacological characterization of SB 234551, a high-affinity and selective nonpeptide ETA receptor antagonist.
Ohlstein EH; Nambi P; Hay DW; Gellai M; Brooks DP; Luengo J; Xiang JN; Elliott JD
J Pharmacol Exp Ther; 1998 Aug; 286(2):650-6. PubMed ID: 9694916
[TBL] [Abstract][Full Text] [Related]
19. Azole endothelin antagonists. 2. Structure-activity studies.
von Geldern TW; Kester JA; Bal R; Wu-Wong JR; Chiou W; Dixon DB; Opgenorth TJ
J Med Chem; 1996 Feb; 39(4):968-81. PubMed ID: 8632420
[TBL] [Abstract][Full Text] [Related]
20. Pharmacology of endothelin receptor antagonists ABT-627, ABT-546, A-182086 and A-192621: in vitro studies.
Wu-Wong JR; Dixon DB; Chiou WJ; Sorensen BK; Liu G; Jae HS; Tasker A; von Geldern TW; Winn M; Opgenorth TJ
Clin Sci (Lond); 2002 Aug; 103 Suppl 48():107S-111S. PubMed ID: 12193066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
